Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prognosis associated mRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) [mRNA]

ABSTRACT: Prognosis associated mRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) [mRNA]

PROVIDER: PRJNA705954 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Prognosis associated mRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) [mRNA]

Project description:Genome wide mRNA profiling in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients of in different prognoses of 28-day. The Agilent SurePrint G3 Human Gene Expression ver. 3 8x60K Microarray was used to obtain RNA profiles in 8 survival patients and 8 dead patients in 28-day.

2021-05-19 | GSE168048 | GEO

Prognosis associated microRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) [miRNA]

Project description:Genome wide microRNA profiling in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients of in different prognoses of 28-day. The Agilent Human miRNA Microarray Kit was used to obtain RNA profiles in 8 survival patients and 8 dead patients in 28-day.

2021-05-19 | GSE168046 | GEO

The Analysis of HBV-ACLF plasma-derived exosomal sncRNA-seq

Project description:To identify the sncRNAs related to HBV-ACLF, we performed small RNA-seq in plasma exosomes collected from 3 normal subjects, 4 chronic hepatitis B (CHB) patients with flare and 6 HBV-ACLF patients in the discovery cohort.

2022-07-27 | GSE202557 | GEO

Prognosis associated mRNA and microRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF)

Project description:Prognosis associated mRNA and microRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF)

| PRJNA705950 | ENA

Prognosis associated microRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) [miRNA]

Project description:Prognosis associated microRNA in peripheral blood mononuclear cells (PBMCs) from hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) [miRNA]

| PRJNA705953 | ENA

Circulating neutrophil transcriptomics in HBV-ACLF patients.

Project description:Circulating neutrophil transcriptomics in HBV-ACLF patients.

| PRJNA692986 | ENA

Circulating neutrophil transcriptomics in HBV-ACLF patients.

Project description:The transcriptomic profiles of circulating neutrophils were compared between patients with ACLF (N=10), patients with CLC (N=10) and HC (N=10). Compared with CLC-neutrophils, the expression of 1022 genes were found to be upregulated in ACLF-neutrophils, and 1101 genes were downregulated. And compared to HC, the expression of 726 genes were up-regulated in ACLF-neutrophils, and 711 genes were down-regulated. The pathway analysis identified mutiple pathways enriched or down-regulated in ACLF-neutrophils when comparing with neutrophils from CLC or HC groups.

2024-02-25 | GSE165024 | GEO

Comparative proteomics analysis of serum protein factors for predicting the prognosis of HBV-related acute-on-chronic liver failure (ACLF)

Project description:Acute-on-chronic liver failure (ACLF) is an acute deterioration of liver function in patients with hepatitis B virus-related cirrhosis. Numerous risk factors were determined to predict the mortality of HBV-related ACLF. However, little is known about the whole serum proteome profiles in ACLF patients. Here, we perform a comparative proteomics analysis to describe the difference of the proteome profiles between the serum samples from survival (S) and death (D) ACLF patients on the day of hospitalization (H) and after four weeks (F) of treatment in hospital. A total of 518 proteins were identified, of which 295 were considered as high-quality proteins (95% peptides ≥ 2). Together, 112 proteins showed significantly different abundant (DAPs). The GO enrichment analysis showed that the DAPs between S and D group at the day of hospitalization were mostly located in lipoprotein particles and synaptic vesicle. Notably, six proteins showed continuously different abundant between S and D groups, both at H and F time point. We further validated three protein factors for predicting the prognosis of ACLF by ELISA in expanded samples, resulting in a 92.22% AUC for combination of ITIH3 and APO-C1 proteins. These proteins may serve as novel factors for predicting the prognosis of HBV-related ACLF. This study provided an overview of proteome profiles between survived and dead ACLF patients and reveals novel serum factors for predicting the prognosis of this extreme condition.

2019-04-19 | PXD013582 |

Quantitative Proteomic Analysis of Plasma Samples from Chronic Hepatitis B and Chronic Liver Failure Patients for Biomarker Discovery

Project description:Hepatitis B virus (HBV)-associated acute on chronic liver failure (HBV-ACLF), characterized by an acute deterioration of liver function in the patients with chronic hepatitis B (CHB), is lack of predicting biomarkers for prognosis. To explore potential biomarkers of HBV-ACLF for clinical applications, immuno-depletion of high-abundance plasma proteins followed by iTRAQ-based quantitative proteomic approach was employed to analyze plasma samples from 20 healthy control people, 20 CHB patients and 20 HBV-ACLF patients, respectively. As a result, a total of 427 proteins were identified and quantified from these samples, and 42 proteins were differentially expressed in HBV-ACLF patients as compared to both CHB patients and healthy controls. According to bioinformatics analysis results, 6 proteins related to immune response (MMR), inflammatory response (OPN, HPX), blood coagulation (ATIII) and lipid metabolism (APO-CII, GP73) were selected as biomarker candidates. Further ELISA analysis confirmed the significant up-regulation of GP73, MMR, OPN and down-regulation of ATIII, HPX, APO-CII in HBV-ACLF plasma samples (p<0.01). Moreover, receiver operating characteristic (ROC) curve analysis revealed high diagnostic value of these candidates in assessing HBV-ACLF. In conclusion, present quantitative proteomic study identified 6 novel HBV-ACLF biomarker candidates and might provide fundamental information for development of HBV-ACLF biomarker.

2018-10-23 | PXD007975 | Pride

The Analysis of HBV-ACLF plasma-derived exosomal sncRNA-seq

Project description:The Analysis of HBV-ACLF plasma-derived exosomal sncRNA-seq

| PRJNA836563 | ENA